Advances of neoadjuvant immune monotherapy or combination therapy in treating locally advanced head and neck squamous cell carcinoma
10.13431/j.cnki.immunol.j.20240000
- VernacularTitle:新辅助免疫单药或联合疗法治疗局部晚期头颈部鳞癌的研究进展
- Author:
Yuyan YANG
1
;
Lei XIA
Author Information
1. 401336,重庆医科大学附属第二医院肿瘤中心
- Keywords:
Locally advanced head and neck squamous cell carcinoma;
Neoadjuvant immunotherapy;
Neoadjuvant immune combination therapy;
Adverse reaction;
Biomarker
- From:
Immunological Journal
2024;40(1):104-111
- CountryChina
- Language:Chinese
-
Abstract:
For patients with locally advanced head and neck squamous cell carcinoma(LA-HNSCC),multi-disciplinary combination therapy based on radical surgery is still the best treatment modality.In recent years,immune checkpoint inhibitors(ICIs)have been successfully applied in the adjuvant therapy of LA-HNSCC,which has aroused great interest in exploring the efficacy and safety of their use in the neoadjuvant therapy.Numerous studies have shown that the application of ICIs in neoadjuvant therapy can increase the major pathological response(MPR)and improve the quality of life without delaying the surgery or increasing the difficulty of surgery and downgrade the subsequent adjuvant therapy.Compared with immune monotherapy,immune combination therapy further increases the pathological remission rate and promotes pathological down-staging with controllable side effects.But the efficacy of the therapy may be affected by various factors such as HPV+/-,tumor microenvironment(TME).Therefore,how to select more suitable biomarkers for patients among the many neoadjuvant immunotherapy regimens is an urgent clinical problem need to be solved.Predictive biomarkers may be one of the bases for developing individualized treatment regimens for LA-HNSCC.Therefore,this article briefly describes the progress of exploratory studies on the optimal sequence of neoadjuvant immunotherapy alone or combinative in LA-HNSCC,and the predictive biomarkers of immunotherapeutic response.
